Conversion to sirolimus in posttransplant renal neoplasms.
BACKGROUND
Calcineurin inhibitors (CNIs) have been associated with the development of posttransplant malignancies, especially lymphoma and solid organ tumors. Sirolimus (SRL) has been shown to inhibit the growth of tumor cell lines in vitro and in vivo and has proven effective in clinical practice for the treatment of Kaposi's sarcoma. Organ transplant patients treated with CNIs who develop a tumor may thus benefit from conversion to SRL.


METHODS
From December 2001 to May 2006, 25 patients who developed a tumor were converted from a CNI-based immunosuppressive regimen to SRL. We analyzed the evolution of the tumor, renal function, and the adverse effects resulting from the change of immunosuppression.


RESULTS
The mean follow-up was 19 months. Creatinine clearance (Cockcroft-Gault) increased from 59.5 +/- 21.7 to 66.0 +/- 24.2 mL/min at 12 months (P = .4) and serum cholesterol from 176.7 +/- 46.8 to 216.4 +/- 40.3 mg/dL (P = .01). Proteinuria rose from 0.3 +/- 0.1 to 1.3 +/- 0.9 g/24 hours (P = .004). Adverse events included anemia, thrombocytopenia, and oral ulcers in 20% of cases, cutaneous eruption and gastrointestinal alterations in 12%, and edema in 24%. Four (16%) patients had improved blood pressure readings. Six (24%) patients died and one experienced an acute rejection episode after conversion to SRL. Nineteen (76%) patients displayed a favorable evolution with no evidence of tumor progression.


CONCLUSIONS
Conversion to SRL stabilized tumor progression in 76% of long-term renal transplant patients who developed a neoplasm over a mean follow-up of 19 months. Moreover, renal function improved. The most important adverse effects were increased cholesterol and proteinuria.
Lopez
V
V
Nephrology Department, Carlos Haya Hospital, Malaga, Spain. verolopezjim@yahoo.es
Gutierrez
C
C
Cabello
M
M
Burgos
D
D
Sola
E
E
Gonzalez-Molina
M
M
D000970:Antineoplastic Agents / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D009369:Neoplasms / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D011183:Postoperative Complications / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D020123:Sirolimus / Q000627:therapeutic use*; D013997:Time Factors
D000970:Antineoplastic Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus